Ken Griffin Belite Bio, Inc Call Options Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLTE
# of Institutions
16Shares Held
78.7KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.1KShares$1.25 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC13.5KShares$839,8800.0% of portfolio
-
Marshall Wace, LLP London, X08.49KShares$529,8650.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$418,3480.0% of portfolio
-
Jpmorgan Chase & CO New York, NY6.36KShares$396,8680.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.55B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...